Suntec has a proprietary MINC technology platform to develop highly effective and safe immunotherapies. MINC applies to neurodegenerative diseases such as Alzheimer's, Parkinson's and immunotherapies for cancer, vaccine, and autoimmune diseases.
Suntec has a pipeline of 10 drug candidates with potentials of "breakthrough" designations. STM-001 was awarded with NIH support to treat glioma, breast, ovarian, gastric, and brain-metastatic cancers. STM-002 in combination with anti-PD-1/PD-L1 can bring the total efficacy/response to 60% (vs 20% for anti-PD-1/PD-L1 alone). Both candidates will enter human trials in 2023.
Suntec has 5 drug candidates for Alzheimer’s and Parkinson’s diseases covering anti-Aβ, anti-tau, anti-α-Synuclein, anti-CD38, and Aβ vaccine. MINC provides high penetration of these protein drugs to the brain. Without MINC platform, these proteins penetrate brain at 0.001-0.1%. With MINC platform, they penetrate at 4-10%. MINC also reduces brain edema caused by these protein drugs.
At this conference, Suntec seeks:
1. Partners to out-license or co-develop its portfolio drugs.
2. Series A funding to support the clinical trials of STM-001 and STM-002.
Suntec has a pipeline of 10 drug candidates with potentials of "breakthrough" designations. STM-001 was awarded with NIH support to treat glioma, breast, ovarian, gastric, and brain-metastatic cancers. STM-002 in combination with anti-PD-1/PD-L1 can bring the total efficacy/response to 60% (vs 20% for anti-PD-1/PD-L1 alone). Both candidates will enter human trials in 2023.
Suntec has 5 drug candidates for Alzheimer’s and Parkinson’s diseases covering anti-Aβ, anti-tau, anti-α-Synuclein, anti-CD38, and Aβ vaccine. MINC provides high penetration of these protein drugs to the brain. Without MINC platform, these proteins penetrate brain at 0.001-0.1%. With MINC platform, they penetrate at 4-10%. MINC also reduces brain edema caused by these protein drugs.
At this conference, Suntec seeks:
1. Partners to out-license or co-develop its portfolio drugs.
2. Series A funding to support the clinical trials of STM-001 and STM-002.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
